Digital Technologies
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.
Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.
Indegene’s CTO talks to Scrip about the state of GenAI implementations in pharma amid hype and limited clarity on ROI, the need to address foundational issues early on, promising pilots, the firm’s alliance with Microsoft and Google’s generalist LLM for therapeutics.
In this week's podcast edition of Five Must-Know Things: Narasimhan plays the long game; Merck & Co’s RSV contender; Mounjaro’s China approval; the mid-cap rising stars; and AI could add billions in drug revenues.
McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.
A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.
Growing geopolitical tensions and a slowing Chinese economy are among the topmost concerns for global business leaders across sectors, a McKinsey study has shown. Separately, in pharma, the BIOSECURE Act continues to occupy centre stage with US House Speaker Johnson recently pledging to push China-targeted legislation before House elections in November
The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence.
As the American Society of Clinical Oncology annual meeting drew to a close, Scrip spoke with industry execs about staying competitive, adjusting to policy changes and how artificial intelligence is advancing cancer R&D.
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
Syntekabio CSO HeaKyoung Cho talks to Scrip how the AI-driven drug development situation in Korea compares with global trends and what the domestic industry needs to do to survive rising competition at home and abroad.
In this week's podcast edition of Five Must-Know Things: Biogen’s immunology acquisition; AstraZeneca looks to cement respiratory lead; why US FTC is tough on pharma; the US election’s impact on pharma; and how new AI tools are impacting medical affairs.
The French drugmaker’s aim is to become the first pharma company powered by artificial intelligence at scale, and the collaborations keep coming.
Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.